» Articles » PMID: 31504825

Medulloblastomas Associated with an APC Germline Pathogenic Variant Share the Good Prognosis of CTNNB1-mutated Medulloblastomas

Abstract

Background: Medulloblastomas may occur in a predisposition context, including familial adenomatosis polyposis. Medulloblastomas related to a germline pathogenic variant of adenomatous polyposis coli (APC) remain rare and poorly described. Their similarities with sporadic WNT medulloblastomas still require description.

Methods: We performed a multicentric retrospective review of 12 patients treated between 1988 and 2018 for medulloblastoma with an identified or highly suspected (personal or familial history) APC germline pathogenic variant. We report personal and familial history APC gene pathogenic variants whenever available: clinical and histologic characteristics of the medulloblastoma, treatments, and long-term outcome, including second tumor and late sequelae.

Results: Medulloblastomas associated with APC pathogenic variants are mainly classic (11/11 patients, 1 not available), nonmetastatic (10/12 patients) medulloblastomas, with nuclear immunoreactivity for ß-catenin (9/9 tested cases). Ten of 11 assessable patients are disease free with a median follow-up of 10.7 years (range, 1-28 y). Secondary tumors included desmoid tumors in 7 patients (9 tumors), 1 thyroid carcinoma, 2 pilomatricomas, 1 osteoma, 1 vertebral hemangioma, and 1 malignant triton in the radiation field, which caused the only cancer-related death in our series.

Conclusions: Medulloblastomas associated with an APC pathogenic variant have an overall favorable outcome, even for metastatic tumors. Yet, long-term survival is clouded by second tumor occurrence; treatment may play some role in some of these second malignancies. Our findings raise the question of applying a de-escalation therapeutic protocol to treat patients with APC germline pathogenic variants given the excellent outcome, and reduced intensity of craniospinal irradiation may be further evaluated.

Citing Articles

Genomic landscape of medulloblastoma subtypes in an Asian cohort.

Han D, Jin X, Li J Transl Cancer Res. 2025; 13(12):6721-6731.

PMID: 39816537 PMC: 11730696. DOI: 10.21037/tcr-24-1350.


Pancancer analysis of the interactions between CTNNB1 and infiltrating immune cell populations.

Xu X, Yang A, Han Y, Li S, Hao G, Cui N Medicine (Baltimore). 2024; 103(44):e40186.

PMID: 39495984 PMC: 11537592. DOI: 10.1097/MD.0000000000040186.


Heterogeneity of tumor microenvironment cell groups in inflammatory and adenomatous polyposis coli mutant colorectal cancer based on single cell sequencing.

Liang L, Zhang C, Han J, Liu Z, Liu J, Wu S Transl Cancer Res. 2024; 13(9):4813-4826.

PMID: 39430845 PMC: 11483422. DOI: 10.21037/tcr-24-689.


Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors.

Hansford J, Das A, McGee R, Nakano Y, Brzezinski J, Scollon S Clin Cancer Res. 2024; 30(11):2342-2350.

PMID: 38573059 PMC: 11147702. DOI: 10.1158/1078-0432.CCR-23-4033.


Germline Variants in Cancer Predisposition Genes in Pediatric Patients with Central Nervous System Tumors.

Jovanovic A, Tosic N, Marjanovic I, Komazec J, Zukic B, Nikitovic M Int J Mol Sci. 2023; 24(24).

PMID: 38139220 PMC: 10744041. DOI: 10.3390/ijms242417387.


References
1.
Kool M, Jones D, Jager N, Northcott P, Pugh T, Hovestadt V . Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014; 25(3):393-405. PMC: 4493053. DOI: 10.1016/j.ccr.2014.02.004. View

2.
Chang C, HOUSEPIAN E, Herbert Jr C . An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969; 93(6):1351-9. DOI: 10.1148/93.6.1351. View

3.
Bertario L, Russo A, Sala P, Eboli M, Giarola M, DAmico F . Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001; 95(2):102-7. DOI: 10.1002/1097-0215(20010320)95:2<102::aid-ijc1018>3.0.co;2-8. View

4.
Clifford S, Lusher M, Lindsey J, Langdon J, Gilbertson R, Straughton D . Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006; 5(22):2666-70. DOI: 10.4161/cc.5.22.3446. View

5.
Jarvis L, Bathurst N, Mohan D, Beckly D . Turcot's syndrome. A review. Dis Colon Rectum. 1988; 31(11):907-14. DOI: 10.1007/BF02554859. View